Studies on Painkillers In Jeopardy

“John Breitner of the University of Washington in Seattle, who led the Alzheimer’s trial, said the hint of risk for naproxen was far from clear from his data, and the main reason his trial shut down was because so many participants were worried about Celebrex.

‘The reasons we had to suspend the treatments had less to with the perception of danger . . . than with other purely practical considerations,’ Breitner said. ‘It’s all very unfortunate.’”

More indication that the case against Naproxyn is pretty shaky.

Related posts:

1. Pfizer’s Adwords run afoul of FDA regulations
2. Sore loser
3. The return of Celebrex
4. Should doctors talk politics with patients?
5. Is the bipolar child and ADHD a purely American phenomenon?
6. Flea’s trial blogging catches a lawyer’s attention
7. Meet the leading provider of buttock augmentation

  Follow on Twitter   Subscribe